-
Something wrong with this record ?
An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart®
M. Vališ, J. Šarláková, S. Halúsková, B. Klímová, P. Potužník, M. Peterka, K. Kuča, P. Štourač, J. Mareš, Z. Pavelek,
Language English Country Great Britain
Document type Clinical Trial, Phase IV, Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't
- MeSH
- Medication Adherence * MeSH
- Adult MeSH
- Injections MeSH
- Interferon beta-1a administration & dosage MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Surveys and Questionnaires MeSH
- Multiple Sclerosis, Relapsing-Remitting drug therapy MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase IV MeSH
- Multicenter Study MeSH
- Observational Study MeSH
- Research Support, Non-U.S. Gov't MeSH
Background: Adherence to Multiple Sclerosis (MS) treatment is considered one of the crucial factors for ensuring optimal clinical outcomes. Research has shown that the use of self-injector devices improves patient compliance with treatment. Therefore, the main purpose of this study is to evaluate the ease of use of RebiSmart® 2.0 in clinically isolated syndrome/relapsing-remitting MS patients during 12 months treatment period.Methods: A total number of 290 subjects entered into data collection; 249 (86%) of them completed the whole 12 months study period. The primary endpoints and the secondary endpoints were assessed by the User Study Questionnaire. Adherence data were retrieved from RebiSmart® 2.0 (Menu - Dose History) on the respective patient's visit. Outcome measures also included Expanded Disability Status Score, Kurtzke Functional Systems, and Modified Social Support Survey, Modified Social Support Survey-5.Results: This study demonstrated a very high proportion (>95%) of patients with a positive rating of the overall ease of use and the overall convenience of RebiSmart®. The proportion of patients with a positive rating of the ease of use by individual domains and the functions of RebiSmart® were also high (>80%).Conclusion: The findings demonstrate a very good perception of the usability of the device by patients overall and in its individual functions.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028208
- 003
- CZ-PrNML
- 005
- 20210114153228.0
- 007
- ta
- 008
- 210105s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/17425247.2020.1742694 $2 doi
- 035 __
- $a (PubMed)32315204
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Vališ, Martin $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic.
- 245 13
- $a An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart® / $c M. Vališ, J. Šarláková, S. Halúsková, B. Klímová, P. Potužník, M. Peterka, K. Kuča, P. Štourač, J. Mareš, Z. Pavelek,
- 520 9_
- $a Background: Adherence to Multiple Sclerosis (MS) treatment is considered one of the crucial factors for ensuring optimal clinical outcomes. Research has shown that the use of self-injector devices improves patient compliance with treatment. Therefore, the main purpose of this study is to evaluate the ease of use of RebiSmart® 2.0 in clinically isolated syndrome/relapsing-remitting MS patients during 12 months treatment period.Methods: A total number of 290 subjects entered into data collection; 249 (86%) of them completed the whole 12 months study period. The primary endpoints and the secondary endpoints were assessed by the User Study Questionnaire. Adherence data were retrieved from RebiSmart® 2.0 (Menu - Dose History) on the respective patient's visit. Outcome measures also included Expanded Disability Status Score, Kurtzke Functional Systems, and Modified Social Support Survey, Modified Social Support Survey-5.Results: This study demonstrated a very high proportion (>95%) of patients with a positive rating of the overall ease of use and the overall convenience of RebiSmart®. The proportion of patients with a positive rating of the ease of use by individual domains and the functions of RebiSmart® were also high (>80%).Conclusion: The findings demonstrate a very good perception of the usability of the device by patients overall and in its individual functions.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a injekce $7 D007267
- 650 _2
- $a interferon beta 1a $x aplikace a dávkování $7 D000068556
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a adherence k farmakoterapii $7 D055118
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a relabující-remitující roztroušená skleróza $x farmakoterapie $7 D020529
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a klinické zkoušky, fáze IV $7 D017429
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Šarláková, Jana $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic.
- 700 1_
- $a Halúsková, Simona $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic.
- 700 1_
- $a Klímová, Blanka $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic.
- 700 1_
- $a Potužník, Pavel $u Department of Neurology, Faculty of Medicine and University Hospital Plzeň, Charles University in Prague, Plzeň, Czech Republic.
- 700 1_
- $a Peterka, Marek $u Department of Neurology, Faculty of Medicine and University Hospital Plzeň, Charles University in Prague, Plzeň, Czech Republic.
- 700 1_
- $a Kuča, Kamil $u Faculty of Science, Department of Chemistry, University of Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Štourač, Pavel $u Department of Neurology, University Hospital and Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Mareš, Jan $u Department of Neurology, Faculty of Medicine, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Pavelek, Zbyšek $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic.
- 773 0_
- $w MED00193514 $t Expert opinion on drug delivery $x 1744-7593 $g Roč. 17, č. 5 (2020), s. 719-724
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32315204 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114153226 $b ABA008
- 999 __
- $a ok $b bmc $g 1608543 $s 1119388
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 17 $c 5 $d 719-724 $e 20200421 $i 1744-7593 $m Expert opinion on drug delivery $n Expert Opin Drug Deliv $x MED00193514
- LZP __
- $a Pubmed-20210105
